ArticleFrontiers in cardiovascular medicine2025
Levosimendan versus dobutamine in septic cardiomyopathy: a randomized clinical trial on cardiac function and safety.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative efficacy of levosimendan and dobutamine in sepsis-related cardiac impairment: a meta-analysis.European journal of clinical pharmacology · 2026Pooled it
- To the Editor: Levosimendan in sepsis-induced cardiac dysfunction: consolidating evidence within a complex clinical landscape.European journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the clinical efficacy, safety, and impact on outcomes of levosimendan compared with dobutamine in patients with septic cardiomyopathy. Methods: A randomized clinical trial was conducted in patients with septic cardiomyopathy between December 2022 and March 2024. Eligible patients received either levosimendan or dobutamine in addition to standard sepsis treatments. Baseline characteristics, laboratory parameters, pulse index continuous cardiac output, clinical outcomes, and adverse reactions were recorded and compared between the two groups. Results: A total of 50 patients were analyzed, with 25 patients in each group. The mean age was 76.4 (±12.3) years, and 28 patients (56%) were male. Baseline characteristics were comparable between groups. Following treatment, improvements were observed in both groups in left ventricular ejection fracture and levels of cardiac troponin I, B-type natriuretic peptide, cardiac index (CI), lactate, and norepinephrine infusion rate(all Conclusions: In patients with septic cardiomyopathy, levosimendan treatment resulted in greater improvements in cardiac function, hemodynamic stability, and tissue perfusion compared with dobutamine, without an increase in adverse reactions. Further studies are needed to evaluate the long-term effects of levosimendan on clinical outcomes in this patient population. Registration number: ChiCTR2500101261.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.